Literature DB >> 2322010

Stimulation of the recruitment of epidermal Langerhans cells by splenopentin.

S Gruner1, W Diezel, D Strunk, A Zwirner, N Sönnichsen, G J Anhalt.   

Abstract

Splenopentin (SP-5: Arg-Lys-Glu-Val-Tyr), a pentapeptide corresponding to the residues 32-36 of the splenic hormone splenin, increases dose-dependently the number of bone marrow colonies (M and GM colonies). Therefore, we tested the stimulatory effect of SP-5 on the recruitment of epidermal Langerhans cells in skin deprived of these cells. A high dose of cyclophosphamide or dexamethasone led to a drastic decrease of LC density in murine skin with slow and incomplete restoration. SP-5 accelerated Langerhans cell recruitment and led to pretreatment levels of Langerhans cell density in the skin. These results indicate that SP-5 may possibly be used to treat disorders (e.g., HIV infection) where impaired Langerhans cell density and function can lead to secondary cutaneous infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322010     DOI: 10.1007/bf00412738

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  11 in total

1.  Effect of ultraviolet radiation on guinea pig epidermal Langerhans cell cytomembrane: light and electron microscopic studies.

Authors:  D Iacobelli; K Hashimoto; S Takahashi
Journal:  Photodermatol       Date:  1985-06

2.  The influence of haematoporphyrin derivative and visible light on murine skin graft survival, epidermal Langerhans cells and stimulation of the allogeneic mixed leucocyte reaction.

Authors:  S Gruner; H Meffert; H D Volk; R Grunow; S Jahn
Journal:  Scand J Immunol       Date:  1985-03       Impact factor: 3.487

3.  Effect of splenopentin (SP-5) on the antibody formation in immunosuppressed mice.

Authors:  W Diezel; R Eckert; K Forner; N Sönnichsen
Journal:  Exp Clin Endocrinol       Date:  1986-07

4.  Induction and augmentation of mitogen-induced immune interferon production in human lymphocytes by a synthetic thymopoietin pentapeptide.

Authors:  W Diezel; S R Waschke; K Forner
Journal:  Biomed Biochim Acta       Date:  1984

5.  Epidermal Langerhans cells--a target for HTLV-III/LAV infection.

Authors:  E Tschachler; V Groh; M Popovic; D L Mann; K Konrad; B Safai; L Eron; F diMarzo Veronese; K Wolff; G Stingl
Journal:  J Invest Dermatol       Date:  1987-02       Impact factor: 8.551

6.  Effects of physicochemical agents on murine epidermal Langerhans cells and Thy-1-positive dendritic epidermal cells.

Authors:  W Aberer; N Romani; A Elbe; G Stingl
Journal:  J Immunol       Date:  1986-02-15       Impact factor: 5.422

7.  Reduced Langerhans' cell Ia antigen and ATPase activity in patients with the acquired immunodeficiency syndrome.

Authors:  D V Belsito; M R Sanchez; R L Baer; F Valentine; G J Thorbecke
Journal:  N Engl J Med       Date:  1984-05-17       Impact factor: 91.245

8.  Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen.

Authors:  T Audhya; M P Scheid; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

9.  Depletion and repopulation of epidermal dendritic cells after allogeneic bone marrow transplantation in humans.

Authors:  G F Murphy; Y Merot; A K Tong; B Smith; M C Mihm
Journal:  J Invest Dermatol       Date:  1985-03       Impact factor: 8.551

10.  Ultraviolet light depletes surface markers of Langerhans cells.

Authors:  W Aberer; G Schuler; G Stingl; H Hönigsmann; K Wolff
Journal:  J Invest Dermatol       Date:  1981-03       Impact factor: 8.551

View more
  2 in total

Review 1.  Role of Langerhans cells and other dendritic cells in viral diseases.

Authors:  E Sprecher; Y Becker
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 2.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.